Malignant cells succumbing to some forms of radiation therapy are particularly immunogenic and hence can initiate a therapeutically relevant adaptive immune response. This reflects the intrinsic antigenicity of malignant cells (which often synthesize a high number of potentially reactive neo-antigens) coupled with the ability of radiation therapy to boost the adjuvanticity of cell death as it stimulates the release of endogenous adjuvants from dying cells. Thus, radiation therapy has been intensively investigated for its capacity to improve the therapeutic profile of several anticancer immunotherapies, including (but not limited to) checkpoint blockers, anticancer vaccines, oncolytic viruses, Toll-like receptor (TLR) agonists, cytokines, and several small molecules with immunostimulatory effects. Here, we summarize recent preclinical and clinical advances in this field of investigation.
Introduction
Ionizing irradiation constitutes one of the pillars of modern cancer therapy. [1] [2] [3] [4] According to current estimates, indeed, at least 50% of subjects with cancer (all confounded) have received or will receive radiation therapy in the course of their disease. 5, 6 For a long time, radiation therapy was believed to operate in a merely cell-intrinsic manner, i.e., by promoting the death or permanent proliferative arrest of malignant cells upon the establishment of oxidative damage to macromolecules including DNA. [7] [8] [9] [10] [11] [12] More recently, however, it has become clear that the antineoplastic effects of ionizing irradiation also involve a considerable cell-extrinsic component. Irradiated cancer cells release a wide panel of biologically active mediators that act locally to promote the death of bystander cells. [13] [14] [15] These factors include not only reactive oxygen and nitrogen species, [16] [17] [18] but also various potentially cytotoxic (and immunomodulatory) cytokines such as interleukin (IL)-6, 19 IL-8, 20 transforming growth factor b1 (TGFb1), [21] [22] [23] [24] and tumor necrosis factor (TNF). 25 Moreover, radiation therapy can promote a particularly immunogenic form of cell death that eventually stimulates the activation of a tumor-targeting immune response with systemic therapeutic potential. [26] [27] [28] [29] [30] [31] [32] The capacity of ionizing irradiation to stimulate anticancer immunity upon the induction of immunogenic cell death (ICD) explains the so-called abscopal or out-of-field effect, i.e., the relatively rare but sometimes very pronounced clinical response to radiation therapy that can manifest in distant, non-irradiated lesions. [33] [34] [35] [36] [37] [38] Finally, some forms of radiation therapy promote the normalization of the tumor vasculature, hence improving the access of chemotherapeutic agents and immune effector cells to malignant lesions. [39] [40] [41] For the purpose of this Trial Watch, radiation therapy can be broadly subdivided into two major therapeutic paradigms: external-beam radiotherapy (EBRT) and internal radiotherapy. 3, 4 In the former setting, malignant lesions are treated across the intact skin, according to collimation procedures that can concentrate the irradiation energy on very specific areas of the tumor. 42, 43 In the latter setting, radionuclides are brought in direct contact with transformed cells, either as pellets that are deposited within the tumor mass (a strategy that is known as brachytherapy), or upon conjugation with (or encapsulation within) tumor-targeting agents, including monoclonal antibodies (mAbs). [44] [45] [46] Both types of radiation therapy are associated with acute and chronic side effects. [47] [48] [49] [50] Acute side effects stem from the unavoidable (but ever more limited, thanks to the technological advances in modern irradiators for clinical use) damage temporarily imposed by irradiation on particularly radiosensitive healthy tissues (like the skin) and often resolve in a few days/weeks after interruption. 44, 51 On the contrary, the chronic toxicity of radiation therapy originates from the permanent damage possibly imposed by considerable radiation doses to stem cell compartments like intestinal crypts, 44, 51 coupled to the establishment of dysregulated chronic inflammatory processes. 52 Moreover, radiation therapy has been linked to a small but non-negligible increase in incidence of secondary, treatment-related malignancies later in life. [53] [54] [55] Throughout the past five decades, several strategies have been conceived to improve the therapeutic index of radiation therapy by either improving efficacy (radiosensitization) and/ or by selectively limiting toxicity to normal tissues (radioprotection). 2, [56] [57] [58] Multiple molecules have been shown to mediate consistent radiosensitization or radioprotection in rodent models of radiation therapy. 42 However, the antioxidant amifostine (also known as Ethyol Ò ) remains the only agent that is licensed by the US Food and Drug Administration (FDA) for use as a radioprotector in humans. [59] [60] [61] [62] [63] One of the most common practices in radiation oncology is dose fractionation, i.e., the delivery of the total irradiation dose in multiple fractions (therapy sessions spaced by at least 6 h) over several days or weeks. 64, 65 Fractionation exploits the improved capacity of normal over malignant tissues to repair the damage imposed by irradiation, hence maximizing its therapeutic window. 64, 65 Importantly, total dose and delivery schedule have a prominent impact on the ability of radiation therapy to promote ICD and hence drive the establishment of a therapeutically relevant anticancer immune response. 28, 64, 66, 67 Classically, radiation therapy has been employed in the context of combinatorial treatment regimens (involving surgery and chemotherapy), either with a curative objective (i.e., with the aim to eradicate primary neoplasms or prevent recurrence) or with a palliative intent (i.e., to limit the pain/discomfort caused by malignancies at specific anatomical locations). 5, 6 Along with the recognition that radiation therapy can mediate potent immunostimulatory effects, considerable interest has been attracted by combinatorial regimens involving EBRT plus one (or more) immunotherapeutic agent(s), [68] [69] [70] [71] 
Published literature-highlights
On 2016 May 1st, querying PubMed with the string "cancer AND radiation therapy AND (2014 OR 2015 OR 2016)" returned more than 23,000 entries, which gives a good indication on the continuous interest of scientists and clinicians in radiation oncology (source http://www.ncbi.nlm.nih.gov/ pubmed). Obviously, a considerable fraction of such an extremely abundant literature deals with the cancer cell-intrinsic effects of radiation therapy.
Among these reports, we found of particular interest (and at least partially related to immunotherapy) the works of: (1) [114] [115] [116] may constitute a promising target for radiosensitization owing to its role in non-homologous end-joining 117 DNA repair. 118 Moreover, approximately 600 PubMed entries of those mentioned above contained the keyword "immunotherapy," dealing (from an experimental or theoretical perspective) with the possibility to combine radiation therapy with anticancer immunotherapy in vitro, in vivo or in patients (source http://www.ncbi.nlm. nih.gov/pubmed). Of these studies, we found of special interest the work of: (1) Deng and colleagues (from the University of Chicago, Chicago, Illinois, US), who not only demonstrated that radiation therapy and checkpoint blockade with antibodies specific for CD274 (best known as PD-L1) 119 synergize to promote antitumor immunity in mice, but also reported that transmembrane protein 173 (TMEM173; best known as STING) [120] [121] [122] signaling in dendritic cells (DCs) is essential for the elicitation of antitumor immune responses by radiation therapy; 123, 124 (2) Denham and collaborators (from the University of Newcastle, Newcastle, Australia), who showed that zoledronic acid, an immunostimulatory agent that targets immunosuppressive tumor-associated macrophages (TAMs), [125] [126] [127] [128] [129] synergizes with radiation therapy and intermediate-term androgen deprivation in the treatment of patients with locally advanced prostate carcinoma; 130 (5) Twyman-Saint Victor and collaborators (University of Pennsylvania, Philadelphia, PA, US), who identified in the upregulation of PD-L1 a common mechanism whereby human and murine tumors become resistant to radiation therapy plus checkpoint blockers specific for cytotoxic T lymphocyte-associated protein 4 (CTLA), and demonstrated that anti-PD-L1 antibodies can be efficiently employed to revert resistance (at least in mice). 138 Moreover, one of our laboratories provided proof-ofprinciple clinical evidence in support of the possibility to combine local radiation therapy with recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) to increase the incidence of therapeutically relevant abscopal effects in patients with advanced solid tumors. 139 Finally, we demonstrated that the so-called immunoscore (a multiparametric biomarker conveying quantitative and spatial information on the immunological tumor infiltrate) 140 not only conveys prognostic information for patients with rectal carcinoma treated by primary surgery, but also predicts clinical response to preoperative chemoradiation. 141 Besides unveiling parts of the mechanism whereby cancer cells may become resistant to the cytostatic and cytotoxic effects of irradiation, these findings lend additional support to the notion that radiation therapy and immunotherapy may be conveniently combined to improve disease outcome in cancer patients.
Ongoing studies
In the period of time elapsing since the publication of the latest Trial Watch dealing with topic (2014 July 1 st ) 42 through 2016 May 1st, no less than 620 clinical studies testing the safety and efficacy of anticancer therapeutic regimens based on (or at least involving) EBRT have been initiated (source: https://clinical trials.gov/). Nearly one-third of these studies (210 trials) investigates the clinical profile of EBRT as a standalone therapeutic intervention, in particular among patients affected by breast carcinoma (34 studies), prostate cancer (44 studies), non-small cell lung carcinoma (NSCLC; 15 studies), and hepatocellular carcinoma (14 studies). Some additional 220 trials initiated between 2014 July 1st and 2016 May 1st assess the safety and efficacy EBRT in combination with various chemotherapeutic regimens, for the most part among individuals with head and neck cancer (34 studies), esophageal cancer (32 studies), pancreatic carcinoma (25 studies), and NSCLC (19 studies).
Finally, approximately 70 of these trials evaluate the therapeutic profile of EBRT combined with targeted anticancer agents, including tumor-targeting mAbs such as the epidermal growth factor receptor (EGFR)-specific molecule cetuximab, [142] [143] [144] [145] or with various alternative non-immunotherapeutic interventions, like hyperthermia or nanoparticles. Since all these studies do not involve bona fide immunotherapeutic agents, we will not discuss them in further detail here. Rather, we will focus on 95 clinical trials initiated between 2014 July 1st and 2016 May 1st that aim to evaluate the safety and efficacy of EBRT combined with immunomodulatory mAbs including checkpoint blockers (66 studies), adoptive cell transfer (4 studies), TLR agonists (4 studies), DC-based vaccination (5 studies), recombinant cytokines (4 studies), peptide-based vaccines (3 studies), oncolytic virotherapy (2 studies), or other immunostimulatory agents (10 studies) (source: https://clinicaltrials.gov/).
The safety and efficacy of EBRT combined with the FDAapproved CTLA4-targeting checkpoint blocker ipilimumab 36, 146, 147 alone or with ipilimumab plus the experimental TLR9 agonist SD-101 94, [148] [149] [150] is being assessed in cohorts of melanoma patients (NCT02406183, NCT02662725), NSCLC patients (NCT02221739), 151 lymphoma patients (NCT02254772), 152 and individuals with advanced solid tumors (NCT0223 9900). EBRT is being tested together with nivolumab, an FDAapproved checkpoint blocker targeting programmed cell death 1 (PDCD1; best known as PD-1), [153] [154] [155] alone or in combination with cytotoxic chemotherapy or targeted anticancer agents, in patients with breast carcinoma (NCT02499367), glioblastoma (NCT02617589, NCT02667587), head and neck squamous cell carcinoma (HNSCC) (NCT02684253, NCT02764593), melanoma (NCT02716948), and NSCLC (NCT02768558). In addition, EBRT plus a combined immunotherapeutic regimen involving both ipilimumab and nivolumab is being assessed for safety and efficacy in individuals affected by melanoma (NCT02659540) or intracranial metastases originated from NSCLC (NCT02696993). The clinical profile of EBRT given in combination with yet another FDA-approved PD-1-targeting checkpoint blocker, i.e., Abbreviations: 3D-CRT, 3D conformal radiotherapy; CAPOX, capecitabine plus oxaliplatin; CTL, cytotoxic T lymphocyte; DC, dendritic cell; EBRT, external beam radiation therapy; HIGRT, hypofractionated image-guided radiotherapy; HNSCC, head and neck squamous cell carcinoma; HRT, hypofractionated radiation therapy; HSRT, hypofractionated stereotactic radiation therapy; IFN-b, interferon b; IMRT, intensity-modulated radiation therapy; NSCLC, non-small cell lung carcinoma; SART, stereotactic ablation radiation therapy; SBRT, stereotactic body radiation therapy; SCLC, small cell lung carcinoma; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy; WFRT, wide-field radiation therapy.
pembrolizumab, [156] [157] [158] [159] [160] generally alone or in the context of conventional chemotherapeutic regimens, is being investigated among patients with HNSCC (NCT02289209, NCT02296684, NCT02402920, NCT02586207, NCT02609503, NCT02641093, NCT02707588, NCT02759575, NCT02775812, NCT02777385), lung carcinoma (NCT02444741, NCT02492568, NCT02621398, NCT02658097), bladder carcinoma (NCT02560636, NCT02621151, NCT02662062), brain tumors (NCT02530502, NCT02313272), colorectal carcinoma (NCT02437071, NCT02586610), 161 gastroesophageal cancer (NC T02730546), breast carcinoma (NCT02303366, NCT02730130), endometrial cancer (NCT02630823), melanoma (NCT02562625), pancreatic carcinoma (NCT02305186), renal cell carcinoma (NCT02599779), thoracic tumors (NCT02587455), or advanced solid tumors of multiple derivation (NCT02303990, NCT0 2318771, NCT02407171, NCT02608385). In addition, EBRT plus pembrolizumab-based immunotherapy is being tested in combination with a genetically modified allogenic cancer cell-based vaccine (GVAX) [162] [163] [164] in subjects with pancreatic cancer (NCT02648282), or together with intratumoral autologous DCs [165] [166] [167] [168] [169] [170] [171] in patients with lymphoma (NCT02677155) ( Table 1) .
Additional (hitherto experimental) checkpoint blockers that are being investigated for their capacity to synergize with EBRT include: (1) atezolizumab, a mAb specific for PD-L1, 119, [172] [173] [174] [175] which is administered together with EBRT alone or with EBRT plus conventional chemotherapy to NSCLC patients (NCT02400814, NCT02463994, NCT02525757, NCT025994 54); (2) avelumab, another PD-L1-targeting mAb, [175] [176] [177] which is given to Merkel cell carcinoma patients in combination with EBRT (as a measure to upregulate MHC Class I expression by cancer cells) and optionally autologous T lymphocytes genetically redirected against tumor-associated antigens (TAAs) (NCT02584829); (4) the PD-L1-specific mAbs durvalumab, 178 which is tested in combination with EBRT alone, EBRT plus chemotherapy, or EBRT plus the CTLA4-targeting agent tremelimumab 179, 180 in patients with esophageal cancer (NCT02 735239), glioblastoma (NCT02336165) small cell lung carcinoma (NCT02701400), and advanced solid tumors (NCT02 639026), and MEDI4736, [181] [182] [183] [184] which is studied in combination with EBRT plus tremelimumab in subjects with unresectable pancreatic cancer (NCT02311361); (5) a new mAb specific for PD-1, namely, REGN2810, whose safety and efficacy in combination with EBRT plus cyclophosphamide-based chemotherapy and recombinant GM-CSF are assessed in patients with advanced solid neoplasms (NCT02383212); 185 (6) a novel fusion protein-targeting PD-1 (called AMP-224; source http:// www.cancer.gov/publications/dictionaries/cancer-drug?cdridD 700595), which is tested together with EBRT in colorectal carcinoma patients (NCT02298946); (7) tremelimumab, whose clinical profile in combination with EBRT is investigated in breast carcinoma patients (NCT02563925); and IPH2201, a mAb specific for killer cell lectin-like receptor C1 (KLRC1; an inhibitory NK-cell receptor best known as NKG2A), [186] [187] [188] which is studied together with EBRT in HNSCC patients (NCT02331875) ( Table 1) .
The following immunostimulatory antibodies that do not operate as checkpoint blockers are also being evaluated for their safety and efficacy when administered in combination with EBRT: (1) the FDA-approved mAb adalimumab, an inhibitor of TNF and hence of immunosuppressive TAMs, [189] [190] [191] [192] [193] which is tested together with EBRT in patients with anaplastic thyroid tumors (NCT02516774); (2) fresolimumab, a mAb that neutralizes TGFb1, 22, 66, [194] [195] [196] [197] which is studied in combination with EBRT in individuals with NSCLC (NCT02581787); and (3) varlilumab, an immunostimulatory mAb specific for CD27, [198] [199] [200] [201] which is assessed for its capacity to improve the efficacy of EBRT in subjects with prostate carcinoma (NCT02284971) ( Table 1) .
As for immunotherapies not based on checkpoint blockers and other immunostimulatory antibodies, EBRT is being evaluated in combination with: (1) autologous DCs expanded ex vivo in the presence of tumor cell lysates 202, 203 in children with advanced solid tumors (NCT02496520) or in Grade IV glioma patients (NCT02772094); (2) unmodified autologous DCs re-infused upon expansion ex vivo, in subjects with NSCLC concurrently receiving standard-of-care platinum-based chemotherapy 204, 205 (NCT02662634); (3) an autologous DC-based vaccine specific for mutant isocitrate dehydrogenase (NADP C ) 1, cytosolic (IDH1) [206] [207] [208] in glioma patients bearing IDH1 R132H (NCT02771301); and (4) vaccines based on TAA-derived peptides or heat-shock protein (HSP)-enriched preparations of tumor lysates 209 in glioma patients (NCT02287428, NCT0272 2512) or women with cervical carcinoma concurrently receiving cisplatin-based chemotherapy (NCT02722512); (5) FDA-approved 90, 210 or experimental 211 oncolytic viruses in individuals with soft tissue sarcoma (NCT02453191) or children with brain malignancies (NCT02457845) ( Table 2 ).
In addition, the safety and efficacy of EBRT combined with immunotherapy is being assessed in the context of (1) adoptive cell transfer, 87, 212 in colorectal cancer patients receiving autologous DCs plus cytokine induced killer (CIK) cells along with FOLFOX (folinic acid plus 5-fluoruracil plus oxaliplatin) chemotherapy (NCT02202928), sarcoma patients treated with autologous CD8 C cytotoxic T lymphocytes (CTLs) genetically modified to recognize the TAA NY-ESO-1 (NCT02319824), and hepatocellular carcinoma patients receiving highly purified autologous CD8 C CTLs (NCT02678013); (2) TLR stimulation, 94 in soft tissue sarcoma patients receiving the experimental TLR4 agonist glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) 213 ,214 (NCT02180698), lymphoma patients concurrently administered with the experimental TLR9 agonist SD-101 215, 216 (NCT02266147), and melanoma patients co-treated with the FDA-approved TLR7 agonist imiquimod [217] [218] [219] [220] [221] (NCT02394132); and (3) relatively unspecific immunostimulation with recombinant IL-2 or GM-CSF in patients with renal cell carcinoma (NCT02306954), glioblastoma (NCT02 663440), and NSCLC (NCT02735850), with thymalfasin (a recombinant version of the human T H 1-skewing peptide thymosin a1) 222 in colorectal cancer patients (NCT02535988), lung cancer patients (NCT02542137, NCT02542930), and esophageal cancer patients (NCT02545751), with TAM-targeting agents like trabectedin [223] [224] [225] or zoledronic acid 128, 226 in subjects with soft tissue sarcoma (NCT02275286) or metastatic NSCLC (NCT02480634), with a chemical inhibitor of IDO1 (i.e., indoximod) 196, 227 in children with brain tumors concurrently receiving temozolomidebased chemotherapy (NCT02502708), with chemical inhibitors of the TGFb1 receptor [228] [229] [230] in breast carcinoma patients (NCT025 38471) and rectal carcinoma patients concurrently treated with standard-of-care chemotherapy (NCT026887129), and with celecoxib, an inhibitor of the immunosuppressive enzyme prostaglandin-endoperoxide synthase 2 (PTGS2; best known as COX2), 231, 232 in HNSCC patients (NCT02739204) ( Table 2) . With a single exception, all these studies are ongoing (i.e., they are listed as "Active, not recruiting," "Not yet recruiting" or "Recruiting" by official sources). NCT02662725, a Phase II clinical trial testing stereotactic radiosurgery plus ipilimumabbased immunotherapy in melanoma patients with brain metastases, appears as "Completed." To the best of our knowledge, however, he results of this study have not yet been disseminated (sources: https://clinicaltrials.gov/; http://www.ncbi.nlm.nih. gov/pubmed; and http://meetinglibrary.asco.org/abstracts;).
Concluding remarks
Total-body irradiation has been extensively employed in the clinic as a myelo-and lymphoablating measure to pre-condition hematopoietic stem cell transplantation recipients. 233 Nonetheless, it is now well established that the localized, targeted irradiation of malignant lesions in the context of dose Abbreviations: 3D-CRT, 3D conformal radiotherapy; ACT, adoptive cell transfer; CIK, cytokine induced killer; CRT, conformal radiotherapy; CTL, cytotoxic T lymphocyte; DC, dendritic cell; EBRT, external beam radiation therapy; FOLFOX, folinic acid plus 5-fluoruracil plus oxaliplatin; GLA-SE, glucopyranosyl lipid adjuvant in stable emulsion; GM-CSF, granulocyte macrophage colony-stimulating factor; HIMRT, hypofractionated intensity-modulated radiation therapy; HNSCC, head and neck squamous cell carcinoma; HSP, heat-shock protein; HSV-1, herpes simplex virus type 1; IDO1, indoleamine 2,3-dioxygenase 1; IFN-b, interferon b; IL-2, interleukin-2; mAb, monoclonal antibody; NSCLC, non-small cell lung carcinoma; RFA, radiofrequency ablation; RT, radiation therapy; SBRT, stereotactic body radiation therapy; SCLC, small cell lung carcinoma; TAM, tumor-associated macrophage; TGFBR1, transforming growth factor b receptor 1; TLR, toll-like receptor. Ã initiated between 2014, July 1st and 2016, May 1st.
fractionation within the standard therapeutic range promotes direct antineoplastic effects while eliciting a therapeutically relevant anticancer immune response. 234 Thus, radiation therapy currently stands out as an accessible and promising tool for improving the efficacy of immunotherapeutic agents as diverse as checkpoint blockers, immunostimulatory antibodies, anticancer vaccines, oncolytic viruses, recombinant cytokines, TLR agonists, and small molecules that repolarize the tumor microenvironment. The clinical activity of all these immunotherapeutic interventions (and presumably that of many chemotherapeutic agents as well) 29 relies indeed on the activation of a robust and polyclonal tumor-specific immune response, and radiation therapy has been convincingly demonstrated to promote such a response by favoring the release of immunostimulatory signals by dying cancer and stromal cells, hence improving their adjuvanticity. 31, 235 Intriguingly, fractionated radiation appears to be superior to single-dose radiation therapy in its capacity to trigger anticancer immune responses in vivo. 64, 236 This has been linked to improved capacity of fractionated radiation (as compared to single-dose radiation therapy) to induce the release of damage-associated molecular patterns (DAMPs) by the tumor. 237, 238 In addition, it may reflect (at least in part) the capacity of fractionated (but not single-dose) radiation to temporarily allow for the survival of malignant cells accumulating genetic and genomic defects that result in exacerbated antigenicity. [239] [240] [241] This intriguing hypothesis has not yet been formally addressed. Irrespectively, by virtue of its well-established efficacy and safety profile, radiation therapy lies together with chemotherapy and immunotherapy at the core of a multimodal therapeutic regimen that holds great promise for the future of clinical tumor immunology.
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